These results indicate that the myeloid cells exhibit both proimmune and immunosuppressive activities in CRC, and the IGLC2+ plasma cells and cycling B cells in CRC can recruit CCR5+ T cells to tumor lesions. The gene discussed is IGLC2; the disease is colorectal carcinoma.